Literature DB >> 12786826

Subclinical activation of latent cytomegalovirus (CMV) infection and anti-CMV immune response in patients with atopic dermatitis.

W-D Döcke1, C Kiessling, M Worm, M Friedrich, A Pruss, M Weitz, S Prösch, F Kern, H-D Volk, W Sterry, K Asadullah.   

Abstract

BACKGROUND: Microbiological infections are considered to be of pathophysiological importance in atopic dermatitis (AD). As yet, no information is available regarding cytomegalovirus (CMV) infection in this disease. This, however, is of interest because of the high prevalence of latent infections in the general population, the frequent reactivation in inflammatory diseases, and the immunomodulating capacity of CMV.
OBJECTIVES: To investigate the prevalence of latent CMV infection, the frequency of active CMV infection, and the immune response to CMV in patients with moderate to severe AD. Methods To detect active infection we analysed CMV antigen expression by peripheral blood mononuclear cells (PBMC) from 27 patients with moderate to severe AD in comparison with 53 healthy volunteers. We used three monoclonal antibodies recognizing different CMV-encoded antigens and immunocytological staining (alkaline phosphatase-antialkaline phosphatase technique).
RESULTS: Patients with AD had a higher mean frequency of CMV-positive PBMC: 2.25 per 10 000 vs. 0.74 per 10 000 in controls (P = 0.001) as well as a higher incidence of CMV antigenaemia: 29.6% vs. 7.5% (P < 0.01). Seropositivity for anti-CMV IgG antibodies indicated subclinical activation of latent infection. Remarkably, a clearance of CMV antigenaemia was observed during anti-eczematous treatment. Significantly higher plasma levels of tumour necrosis factor-alpha, which is involved in CMV reactivation, and interleukin-12, which is crucial for an antiviral cellular immune response, were observed in AD patients in comparison with healthy volunteers. Furthermore, a significantly enhanced frequency of circulating activated HLA-DR+ T cells especially in CMV-seropositive AD patients (19.3% vs. 13.5% in seronegative AD patients vs. 10.2% in controls) suggested that the active CMV infection triggers a cellular immune response. This was also supported by a high frequency of CMV-specific interferon-gamma-producing T cells in CMV-seropositive patients with AD.
CONCLUSIONS: Our data suggest that active, subclinical CMV infection is more frequent in patients with moderate to severe AD and may have immunopathophysiological relevance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12786826     DOI: 10.1046/j.1365-2133.2003.05263.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  12 in total

1.  Hypertensive iridocyclitis.

Authors:  E C Kim; T P Margolis
Journal:  Br J Ophthalmol       Date:  2006-07       Impact factor: 4.638

2.  HCMV-encoded UL128 enhances TNF-α and IL-6 expression and promotes PBMC proliferation through the MAPK/ERK pathway in vitro.

Authors:  Qi Zheng; Ran Tao; Huihui Gao; Jun Xu; Shiqiang Shang; Ning Zhao
Journal:  Viral Immunol       Date:  2012-04       Impact factor: 2.257

Review 3.  Cytomegalovirus reactivation in critically ill immunocompetent hosts: a decade of progress and remaining challenges.

Authors:  Charles H Cook; Joanne Trgovcich
Journal:  Antiviral Res       Date:  2011-03-23       Impact factor: 5.970

4.  Risk of herpesvirus, serious and opportunistic infections in atopic dermatitis: a population-based cohort study.

Authors:  J Wan; D B Shin; M N Syed; K Abuabara; A R Lemeshow; J M Gelfand
Journal:  Br J Dermatol       Date:  2022-01-20       Impact factor: 11.113

5.  Detection of human cytomegalovirus in different histological types of gliomas.

Authors:  Michael E Scheurer; Melissa L Bondy; Kenneth D Aldape; Thomas Albrecht; Randa El-Zein
Journal:  Acta Neuropathol       Date:  2008-03-20       Impact factor: 17.088

6.  CD8+ T cell activation and differentiation in allergic asthma and the impact of cytomegalovirus serological status.

Authors:  K Bratke; L Krieghoff; M Kuepper; W Luttmann; J C Virchow
Journal:  Clin Exp Immunol       Date:  2007-05-18       Impact factor: 4.330

Review 7.  Clinical consequences of asymptomatic cytomegalovirus in treated human immunodeficency virus infection.

Authors:  Samuel R Schnittman; Peter W Hunt
Journal:  Curr Opin HIV AIDS       Date:  2021-05-01       Impact factor: 4.283

8.  Cytomegalovirus-induced immunopathology and its clinical consequences.

Authors:  Stefania Varani; Maria Paola Landini
Journal:  Herpesviridae       Date:  2011-04-07

9.  Nonsteroidal Anti-Inflammatory Drugs Quickly Resolve Symptoms Associated with EBV-Induced Infectious Mononucleosis in Patients with Atopic Predispositions.

Authors:  Itsuro Kazama; Chieko Miura; Toshiyuki Nakajima
Journal:  Am J Case Rep       Date:  2016-02-14

10.  Valaciclovir to prevent Cytomegalovirus mediated adverse modulation of the immune system in ANCA-associated vasculitis (CANVAS): study protocol for a randomised controlled trial.

Authors:  Dimitrios Chanouzas; Lovesh Dyall; Peter Nightingale; Charles Ferro; Paul Moss; Matthew David Morgan; Lorraine Harper
Journal:  Trials       Date:  2016-07-22       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.